Sangamo Therapeutics (SGMO) Tops Q4 EPS by 37c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. MSFT
3. PLTR
4. SPY
5. CSCO
6. KTOS
7. JPM
8. DT
9. AON
10. TMUS

Go back to Sangamo Therapeutics (SGMO) Tops Q4 EPS by 37c

Sangamo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

February 28, 2020 7:00 AM EST

Conference Call and Webcast Scheduled for 8 a.m. Eastern Time

BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2019 financial results and recent business highlights.

This quarter marked an important milestone for Sangamo, as we transitioned to a Phase 3 company following the transfer of the IND for SB-525 hemophilia A gene therapy to our partner Pfizer, who plan to commence the registrational study this year. This is a significant step in our mission to bring our genomic... More